Review article
Novelties in immunotherapy of esophageal and stomach cancer
Vesna Bišof
orcid.org/0000-0002-2826-9664
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia; Osijek University School of Medicine, Osijek, Croatia
Abstract
A high frequency of somatic mutations has been detected in stomach and esophageal cancers which makes them a possible suitable target for the application of immunotherapy. Contemporary immunotherapeutic approaches rely on monoclonal antibodies that inhibit immune checkpoints. The results of early clinical studies are promising, while only a few phase III studies have published their results so far. A particulary promising treatment strategy is the combination of checkpoint inhibitors with other treatment modalities, such as chemotherapy, targeted therapy, radiotherapy or T cells agonists.
Keywords
esophageal cancer; gastric cancer; checkpoint inhibitors; immunotherapy
Hrčak ID:
192191
URI
Publication date:
21.12.2017.
Visits: 1.749 *